CCR9 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes carrying targeted disruptions of the CCR9 gene. This polyclonal knockout pool provides a heterogeneous loss-of-function model that reflects population-level effects of CCR9 ablation, avoiding clonal selection bias. CRISPR/Cas9-mediated gene disruption was employed to generate these cells, which are suitable for functional studies of CCR9-dependent processes.
The Raji cell line is an EBV-positive Burkitt lymphoma-derived lymphoblastoid line of B lymphocyte origin. Established from a patient with Burkitt lymphoma, Raji cells exhibit features of mature B cells and are extensively used to study B cell biology, antigen presentation, and chemokine receptor signaling. Their suspension growth and robust migratory behavior make them an ideal host for chemotaxis and adhesion assays.
CCR9 encodes a G protein-coupled receptor that binds the chemokine CCL25. Upon ligand engagement, CCR9 activates G??i proteins, triggering PI3K/Akt and MAPK/ERK cascades, leading to ERK1/2 phosphorylation, NF-??B and AP-1 activation, and calcium mobilization. Signaling also promotes integrin ??4??7 activation, which mediates lymphocyte adhesion and gut homing. CCR9 expression is regulated by retinoic acid, TGF-??, and inflammatory cytokines, while receptor desensitization involves GRK and ??-arrestin. Knockout of CCR9 disrupts CCL25-induced chemotaxis and downstream signaling responses.
In the Raji B lymphocyte background, CCR9 knockout abrogates migration toward CCL25, providing a relevant model for studying lymphoma cell trafficking and gut-homing mechanisms. The EBV-positive status of Raji cells allows exploration of viral influences on chemokine signaling. Additionally, the antigen-presenting capacity of Raji cells makes this knockout useful for investigating the role of CCR9 in B cell?CT cell interactions during mucosal immune responses.
These polyclonal knockout cells support Transwell migration and chemotaxis assays toward CCL25, adhesion assays measuring integrin ??4??7 activation, and intracellular signaling analyses via flow cytometry or western blotting for phospho-Akt and phospho-ERK. They are valuable for drug target validation in inflammatory bowel disease, celiac disease, and colorectal cancer, as well as for mechanistic studies of CCR9 signaling in B cell malignancies. For further details and lot-specific information, please contact Ascent Research.
